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Renal nitric oxide production during the early phase of experi- of the mediators implicated in the development of DN
mental diabetes mellitus. is the nitric oxide (NO) system [4]. NO acts as a neuroneal
Background. Diabetic nephropathy (DN) is characterized
and vascular messenger that activates soluble guanylateby hyperfiltration and hypertrophy in experimental models of
cyclase, resulting in increased levels of cGMP. NO acti-diabetes mellitus (DM). Several studies have demonstrated
that the pathophysiologic and morphologic changes in DN are vates multiple intracellular pathways, including endothe-
mediated by either an increase or decrease in renal nitric oxide lium-dependent relaxation, inhibition of platelet aggrega-
(NO) production and/or activity. The goal of the present study
tion and adhesion, and tubuloglomerular feedback (TGF)was to determine the effects that the early diabetic state has
in the kidney [4]. NO synthase (NOS) catalyzes the con-on NO production in the kidney of rats with streptozotocin-
induced DM. version of arginine to citrulline and NO. NOS exists in
Methods. Experimental DM was induced in rats with strep- three main isoforms: neuroneal NOS (nNOS), endothe-
tozotocin. Urinary NO production was measured, and levels
lial NOS (eNOS), and inducible NOS (iNOS). nNOSand activity of the different NOS isoforms were determined
and eNOS are Ca11/calmodulin-dependent, whereas cal-by a combination of techniques, including immunoblotting,
immunohistochemistry, diaphorase staining, and reverse tran- cium-independent iNOS is regulated by a variety of cyto-
scription-polymerase chain reaction. kines. Within the kidney, high levels of nNOS are located
Results. During the first week of DM, urinary NO metabo-
in the macula densa. eNOS is found in glomerular affer-lites (uNO2 1 NO3) were reduced as compared with controls,
ent and efferent arterioles, and iNOS has been localizedwhich were unrelated to changes in serum levels of NO. Total
NO synthase (NOS) activity was reduced in the renal cortex to the cells of the mesangium [5].
beginning at 30 hours after the induction of DM. NADPH The exact role of NO in mediating DN has not been
diaphorase staining of renal cortical slices showed reduced NOS
fully elucidated, and the results of previous studies haveactivity in the macula densa in diabetic animals. By immunohis-
not been consistent with each other. NO appears to medi-tochemical staining with antibodies to the different isoforms
of NOS, it was found that protein levels of the neuroneal NOS ate DN by its effects on both renal hemodynamics and
(nNOS) isoform was diminished in the macula densa. No changes morphology. In experimentally-induced diabetes melli-
were found in the levels of endothelial NOS (eNOS) activity
tus (DM), the elevation of the glomerular filtration rateand protein in the renal cortex in the early diabetic state.
(GFR) was related to an increase in the synthesis andConclusions. This study provides strong evidence that renal
production of NO is reduced in early DM and that this reduc- action of NO [3]. Komers, Allen, and Cooper demon-
tion is associated with decreased levels of nNOS activity and strated that in streptozotocin (STZ) induced DM, uri-
protein in the macula densa.
nary NO metabolites (uNO2 1 NO3) were increased,
and inhibition of NO production by N-nitro-l-arginine
methyl ester (L-NAME), a NOS inhibitor, preventedRenal hypertrophy and hyperfiltration characterize
the increase in GFR that normally accompanies DMthe early stage of diabetic nephropathy (DN) [1–3]. One
in these animals [6]. On the other hand, NO-induced
vascular relaxation is impaired in DM, and this defectKey words: streptozotocin, renal hypertrophy, nephropathy, macula
densa, neuronal nitric oxide synthase. is repaired when l-arginine, a precursor of NO, is pro-
vided in excess, suggesting that early experimental DM
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renal function and structure normally found in STZ- five, and seven days. In preliminary experiments, it was
determined that changes (body weight, glucose level, andinduced experimental DM [8, 9].
The aim of the present study was to characterize renal kidney growth) seen in experimental animals housed in
metabolic cages were similar to those in animals main-NO production and the expression of the various NOS
isoforms in early experimental DM. The relationship tained in regular cages. At the end of the study, the
animals were anesthetized with an intraperitoneal injec-between renal hypertrophy and elevated glomerular fil-
tration seen shortly after the onset of experimental DM tion of sodium pentobarbital, and lung, liver, heart,
spleen, and both kidneys were rapidly removed. Afterand changes in the NO system was also investigated. Our
results indicate that the primary alteration in the renal weighing the kidneys, the left kidney of each experimen-
tal animal was kept intact for preparation of histologicNO system in early DM involves a decrease in the level
of nNOS activity and protein expression in the macula slides, while the right cortex and medulla were separated.
Tissues were stored at 2708C in preparation for thedensa that occurs simultaneously with the increase in
GFR and renal hypertrophy. analytic procedures described later in this article.
Urinary and plasma nitric oxide determination
METHODS
Urine and plasma NO2 1 NO3, the stable metabolites
Materials of NO, were determined by the Griess reaction, after
the reduction of NO3 to NO2 by nitrate-reductase pre-Antibodies to endothelial and nNOS were obtained
from Transduction Laboratories (Lexington, KY, USA). pared in our laboratory [10].
[2,3-3H] l-arginine (43.5 Ci/mmol) was purchased from
Nitric oxide synthase activityNEN DuPont (Savyon, Israel). Aminoguanidine was pur-
chased from Cal-Biochem (La Jolla, CA, USA). N-nitro- Nitric oxide synthase activity in tissue homogenates
was measured by monitoring the conversion of [3H] argi-l-arginine methyl ester (L-NAME), b-nicotinamide
phosphate, NADPH, STZ, and all other materials were nine to [3H] citrulline [11]. Tissues were homogenized
in 50 mmol/L Tris-HCl buffer (pH 7.4) and 1 mmol/Lobtained from Sigma Israel (Rehovot, Israel).
ethylenediaminetetraacetic acid (EDTA). The homoge-
Animals and experimental protocol nates were spun at 10,000 3 g for 10 minutes at 48C. To
remove the endogenous arginine, the supernatants wereThe experiments were conducted on Hebrew University
Sabra male rats weighing approximately 200 g. The ani- collected and incubated with Dowex 50W-X8 (Na1; Bio-
Rad, Hercules, CA, USA) for five minutes at 48C. Themals were maintained and treated in accordance with the
regulations of the Hadassah Committee on Animal Care samples were spun again, and aliquots (500 mg of protein)
were incubated with 10 mmol/L NADPH (reducedand Use and followed the Principles of Laboratory Ani-
mal Care (NIH publication no. 85-23, revised 1985). Rats form), 10 mmol/L CaCl2, 50 mmol/L l-valine, and [3H]
arginine (0.5 mCi) with or without NOS inhibitors [10were housed in a temperature- and humidity-controlled
room with a 12-hour light/dark cycle. The animals were mmol/L L-NAME, egtazic acid (EGTA), or aminoguani-
dine]. After 20 to 50 minutes of incubation at 378C, themaintained on standard laboratory animal chow and pro-
vided water ad libitum. Diabetes was induced by intrave- reaction was terminated by adding 3 mL of ice-cold HEPES
buffer (pH 5.5) containing 2 mmol/L EDTA, and thennous injection of STZ (diluted in Dextrose 5%, pH 4.5)
at a dose of 65 mg/kg body wt. Daily blood glucose passed on a column of Dowex (0.5 mL). A 0.5 mL aliquot
from the eluted [3H] citrulline was quantitated by liquidlevels were monitored with a portable glucose-measuring
device (Glucometer Elite, Bayer, Elkhart, IN, USA) us- scintillation spectroscopy. The total protein concentra-
tion of tissue homogenates was measured (standard Bio-ing blood obtained by tail prick of conscious rats.
The two groups, control and STZ rats, were all aged Rad protein assay).
matched. For measurement of food consumption, uri-
Immunohistochemistrynary and plasma NO metabolites, and creatinine clear-
ance, individual animals were placed in metabolic cages For immunohistochemistry staining, kidney tissue was
snap frozen in isopentane at 2208C, cut in 6 mm thickfor periods of time lasting for seven days. Body weight,
food, and fluid intake were measured. Urine collections sections, and thaw mounted on slides. The slides were
incubated in 4% formaldehyde (pH 7.4) for fixationwere obtained, and blood samples were drawn from an
internal jugular vein. The rats were allowed 48 hours (30 min at room temperature), washed in phosphate-
buffered saline (PBS), pH 7.4, and incubated for blockingof adaptation in the metabolic cages. Plasma and urine
creatinine levels were determined, and the creatinine in PBS, pH 7.4, containing 5% bovine serum albumin
(BSA), and 0.1% Triton X-100 for 20 minutes at roomclearance was calculated by standard laboratory meth-
ods. For the other experiments involving tissue analyses, temperature. This was followed by a 16-hour incubation
at 48C with polyclonal anti-nNOS (1:100 dilution). Subse-rats were housed two per cage for 30 hours and three,
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quently, the slides were washed and incubated with anti- Reverse transcription-polymerase chain reaction
rabbit Alexa-488 green fluorescence (1:200 dilution). Total RNA was isolated from kidney cortex of control
Other slides were incubated with eNOS monoclonal anti- and STZ-diabetic rats at day 5 using TRIzol reagent
body (1:100 dilution) in PBS containing 1% BSA and (GIBCO BRL, Grand Island, NY, USA) according to
0.1% Triton X-100. The slides were washed and incu- manufacturer’s instructions.
bated with the secondary biotinylated horse anti-mouse Reverse transcription followed by DNA amplification
antibody followed by peroxidase-avidin substrates ac- was performed using the access reverse transcription-
cording to the manufacturer’s recommended protocol polymerase chain reaction (RT-PCR) system kit (Pro-
(Vectastain elite ABC kit; Vector Laboratories, Burl- mega, Madison, WI, USA). Varying amounts of total RNA
ingame, CA, USA). were used in the experiments to assure that the assay was
semiquantitative. As a control, deoxynucleotide primers
Diaphorase staining complementary to the rat glyceraldehyde-3-phosphate
Sections of renal tissue, 10 mm thick, prepared from dehydrogenase (GAPDH) primers (sense 59AATGCAT
frozen kidney specimens sections were incubated for CCTGCACCACCAA39 and antisense 59ATACTGT
TACTTATACCGATG39) were utilized under the samefour hours in 4% buffered formaline, pH 7.0, and were
conditions. Specific rat nNOS primers were 59GAATwashed three times in PBS. The frozen sections were
ACCAGCCTGATCCATGG-AAC39 (sense, positionincubated for two hours at 378C in the dark with a sub-
2461 to 2484) and 59TCCTCCAGGAGGGTGTCCAC-strate mixture containing 0.1 mol/L Tris-HCl (pH 7.8),
CGCA39 (antisense, position 3039 to 3062) [11].1 mmol/L b-NADPH, 0.1 mmol/L nitro blue tetrazolium,
The PCR was performed on a PTC-100 DNA thermal0.3% Triton X-100, and 0.1% formaldehyde. All sections
cycler (MJ Research, Watertown, MA, USA). The con-were rinsed with PBS and fixed in Kaiser-glycerol gelatin
ditions for DNA amplification were as follows: Aftersolution according to the method of Ovadia et al [12].
initial denaturation at 948C for two minutes, 35 cyclesThe enzyme activity was evaluated by either counting
of amplification (948C for 1 min, 608C for 1 min, and 728Cthe positive macula densa stained out of 100 glomeruli
for 2 min) were performed, followed by final extension atper group or by counting the number of visible macula
728C for five minutes. The PCR products were separateddensa cells per stained macula. The results are expressed
on an ethidium bromide-stained 1.5% agarose gels.as the mean number of positive stained cells per glomer-
uli [13]. To determine the validity of using frozen tissue
Statistical analysisversus perfused tissue, preliminary experiments were
All values are expressed as mean 6 SEM. Student’sdone with kidney sections from rats perfused with para-
t-test was used to assess statistical significance betweenformaldehyde followed by fixation in formalin and incu-
groups. Statistical significance was defined as P , 0.05.bation in a 30% sucrose solution for three days. Tissue
was otherwise prepared in similar manner and reacted
with NADPH diaphorase. No differences were detected RESULTS
between frozen sections and sections from rats perfused Male Sabra rats weighing approximately 180 to 200 g
with paraformaldehyde. received STZ at a dose of 65 mg/kg body weight and
were killed at various time periods after the inductionImmunoblotting
of DM. Table 1 summarizes the characteristics of these
Samples (50 mg protein) of tissue homogenates were animals and concurrent controls. As expected, animals
separated by sodium dodecyl sulfate-polyacrylamide gel with DM failed to gain weight. In contrast, both kidney
electrophoresis (SDS-PAGE; 7.5% acrylamide) and weight and the kidney:body weight ratio increased in
transferred to Immobilon-P membrane (Millipore, Bed- diabetic animals (statistically significant after 3 days),
ford, MA, USA). Blots were blocked for one hour at indicating renal growth. These changes occurred even
room temperature in 5% nonfat milk and incubated with though food intakes was controlled for both experimen-
monoclonal anti-eNOS antibody (1:1000 dilution) for 16 tal and control animals 16.3 6 1.6 and 17.1 6 1.3 (g),
hours at 48C. After washing in TBS-Tween (0.1%), the respectively.
membrane was incubated with anti-mouse IgG antibody The 24-hour urinary NO2 1 NO3 excretion (Fig. 1) was
conjugated with horseradish peroxidase (1:1000 dilution) lower in STZ-rats from day 3 to the end of experiment,
for one hour at room temperature. The bands were visu- compared with nondiabetic rats despite concurrently oc-
alized by enhanced chemiluminescence (ECL kit; Amer- curring increases in creatinine clearance (Fig. 2). During
sham Pharmacia Biotech, Buckinghamshire, UK). Bands the same period (7 days), plasma NO metabolites were
corresponding to eNOS were quantitated by scanning unchanged (control 24.5 6 1.6 vs. diabetes 25.7 6 1.8
densitometry (OD 3 mm2) of the Western blot autora- mmol/L). These findings suggest that reduced urine NO
metabolites are related to decreased renal production ofdiogram using a Fluro-S-multimager (Bio-Rad).
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Table 1. Physical and biochemical parameters of the control and diabetic rats
Control Diabetes Control Diabetes Control Diabetes Control Diabetes
30 hours 3 days 5 days 7 days
N 5 7 5 6 5 6 5 5
Initial body weight g 176619.5 195617.2 18868 18667 18868 18868 19465 19163
Final body weight g 179614.3 196613 220619 185619 224613 180614 22869 18264
Kidney weight g (L1R)/2 0.6160.03 0.6260.06 0.6660.22 0.7860.09 0.7460.06 0.8160.13 0.7560.01 0.9460.02a
Kidney:body weight ratio 31023 3.460.00 3.260.00 3.060.0 4.260.1b 3.360.0 4.560.0b 3.360.0 5.260.0b
Blood glucose mmol/L 5.661.8 19.963.2b 7.860.8 16.561.3b 7.860.6 22.761.9b 7.760.6 18.361.6b
aP , 0.05, bP , 0.01
Fig. 1. Changes in urinary nitric oxide metabolites (uNO2 1 NO3) in Fig. 2. Creatinine clearance in STZ rats during the first week of diabe-streptozotocin (STZ) rats during the first week of diabetes. Symbols
tes. Symbols are: (d) control; (.) diabetic rats; *P , 0.01 diabetic ratsare: (d) control; (.) diabetic rats; *P , 0.01; **P , 0.05.
vs. control.
NO due to decreased levels of NOS in the kidney. In
equals eNOS 1 nNOS). Additional experiments weresupport of this assumption, it was found that total NOS
done to assess whether the changes in cNOS activity areactivity in the kidney cortex was reduced beginning at
due to changes in protein levels of eNOS or nNOS. Using30 hours despite NOS activity increasing significantly in
a monoclonal antibody specific to eNOS, we found thatthe liver (Table 2). The tissue NOS activity was almost
although eNOS levels tends to increase in the liver ho-negligible in spleen, lung, heart, and kidney medulla even
mogenates of diabetic rats, it did not reach statisticalwhen large amounts (up to 1 mg) of total cellular protein
significance compared with control (2.43 6 0.23, 1.87 6were assayed.
0.65 P 5 0.08, respectively; Fig. 3A). In kidney cortexSeveral studies were performed to determine which
homogenates, five days after the induction of diabetes,renal isoforms of NOS were decreased in early DM. To
eNOS protein levels were the same (control 0.35 6 0.22determine whether iNOS activity was reduced in the
vs. diabetes 0.36 6 0.12; Fig. 3B). We could not visualizecortex, the NOS assay was carried out in the presence
any positive bands to nNOS protein in cortical homoge-of aminoguanidine, as the it is a more selective inhibitor
nates using up to 100 mg of protein from control orof iNOS. Total NOS activity in the cortical homogenate
diabetic animals using a polyclonal antibody to nNOS.did not change either in the experimental or control
However, there are no changes in the levels of nNOSanimals, suggesting that the contribution of iNOS to the
mRNA in the kidney cortex as assessed by RT-PCRoverall NOS activity is negligible. Further evidence that
(Fig. 4).most of the NOS activity is derived from the calcium-
Since no changes in the NOS isoforms could be de-dependent forms was demonstrated after the addition
tected in cortical homogenates, immunohistochemicalof 10 mmol/L EGTA, a calcium chelator, which reduced
staining was utilized to determine whether the diabeticNOS activity to background levels.
state induced localized changes in NOS activity and pro-Thus, the changes in kidney cortex and liver NOS
activity (Table 2) are those of cNOS (constitutive NOS tein. Kidney slices from diabetic rats killed at three, five,
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Table 2. Nitric oxide synthase activity in liver and kidney cortex
Control Diabetes Control Diabetes Control Diabetes Control Diabetes
30 hours 3 days 5 days 7 days
N 5 7 5 7 5 6 5 5
Liver 100615 115619 100613 126613a 100623 270630b 100629 15069
Kidney cortex 100616 57618b 100612 53625b 100615 36627b 100618 50617a
Thirty hours to 7 days after induction of diabetes nitric oxide synthase activity was assayed in the tissue homogenates by following the conversion of L-[3H]
arginine to [3H]-citrulline (pmol/min/mg protein) with L-valine (50 mmol/L) present in the assay system. The activity was defined as citrulline formation totally
inhibited by 10 mmol/L L-NAME.
The activity of control rats was determined as 100% in liver and kidney cortex homogenates, 0.045 and 0.0178 pmol/min/mg protein, respectively.
aP , 0.05, bP , 0.01, diabetic rats vs. control
Fig. 3. Western blot analysis of liver and kidney cortex homogenate.
Fifty micrograms of liver (A) or kidney cortex (B) homogenate was
separated on 7.5% SDS-PAGE. After blotting, the membrane was
reacted with monoclonal anti-endothelial nitric oxide synthase (anti-
eNOS) antibody (1:1000). PC, human endothelial cell lysate.
Fig. 5. NADPH-diaphorase staining of sections from normal and dia-
betic rat kidney. (A) Normal rat kidney was prepared and stained as
described under the Methods section (magnification 3400). (B) Popula-Fig. 4. Effect of five days diabetes on expression of neuronal nitric
tion of nNOS positive macula densa of the experimental rats. Twelveoxide synthase (nNOS) mRNA in kidney cortex. A representative ethid-
sections from diabetic (N 5 5) and control (N 5 5) animals were stainedium bromide-stained agarose gel of kidney cortex nNOS (601 bp) and
with NADPH-diaphorase. The number of positive macula densa perGAPDH (515 bp) RT-PCR products. Lanes 1 through 3, control rats;
100 counted glomeruli is expressed in percentage. *P , 0.01.lanes 4 through 6, STZ-diabetic rats.
ing, both in terms of the number of NADPH-diaphorase–and seven days after the induction of DM reacted with
positive macula densa per 100 glomeruli (Fig. 5) and thenitroblue tetrazolium (NADPH diaphorase), an indica-
number of visibly stained cells per positive macula densator of NOS activity, did not demonstrate any changes in
in the diabetic rats as compared with the controls (3.30 6staining intensity within the glomerulus. However, there
was a significant reduction in nitroblue tetrazolium stain- 0.97 vs. 6.42 6 1.23 on day 5, respectively, P , 0.01).
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is no difference in cellular staining when antibodies to
eNOS are used for immunostaining. In addition, the only
change in NADPH diaphorase staining, a marker for
NOS activity, occurred in the macula densa—an area
known to have high nNOS activity [23]. It is also unlikely
that the source of decreased urinary NO metabolites in
diabetic rats was secondary to decreased systemic NO
production as the plasma NO levels were the same in
the diabetic state as in the control and liver NOS activity
was significantly increased.
Choi et al showed by Western blot that protein levelsFig. 6. Confocal images of the normal kidney sections immunostained
for nNOS. (a) Differential interference contrast (DIC) images were of all three NOS isoforms increased one week after in-
collected simultaneously using a transmitted light detector. (b) A Zeiss duction of diabetes [24]. It should be noted, however,
LSM 410 confocal laser scanning system attached to the Zeiss Axiovert
that the decrease in nNOS activity in the macula densa135M microscope was utilized Green fluorescence of Alexa-488 (sec-
ondary antibody was used at 1:200; Molecular Probes, Eugene, OR, is demonstrated in our study by histologic analysis using
USA) was excited with an argon laser. both an anti-nNOS antibody and diaphorase staining.
There were also no significant alterations in eNOS stain-
ing throughout the cortex, and the only change in
NADPH diaphorase occurred in the macula densa.The decline in NOS activity in the macula densa was
It also appears that the expression of NOS isoformsparalleled by a decrease in the number of stained macula
is an evolving process. In a study by Sugimoto et al,densa (16% stained macula densa in control vs. 2% in
it was demonstrated that eNOS protein and NADPHdiabetic glomeruli on day 5 after the induction of DM), as
diaphorase staining intensity began increasing in the af-detected by immunohistochemistry using the polyclonal
ferent arterioles and glomeruli beginning at one weekanti-nNOS antibody (Fig. 6). No significant changes in
of DM [20]. Yagihashi et al showed that nNOS activitystaining patterns between the control and diabetic state
and NADPH diaphorase staining remain low in the mac-could be detected when the eNOS antibody was utilized
ula densa in prolonged DM [25]. Taken together, the(data not shown).
data suggest that nNOS activity in the kidney declines
very early in DM and remain low, whereas eNOS activity
DISCUSSION is initially stable, as shown by our data, and increases as
the diabetic state is prolonged.The NO system has been implicated in the pathogene-
sis of DN [4]. In pathological conditions, such as in DM, An increase in NO metabolites in the urine and plasma
of diabetic rats was shown before, and the apparenthyperglycemia can induce endothelial dysfunction, which
may result from decreased production of NO or other differences may be due to the different time periods
studied, for example, during a later phase of DM, at afactors that interfere with NO activity [14, 15]. However,
the mechanisms by which changes in the level of NO are time when renal hypertrophy begins to plateau [3, 6, 26].
Moreover, the increase in both plasma and urine NOrelated to renal hemodynamics and morphology occurring
in DM have not been fully elucidated [16–22]. In the metabolites reported by other groups does not necessar-
ily imply increased renal production of NO. It is possiblepresent study, it has been shown that during the early
stage of DM, there is a decrease in urinary NO metabo- that increased NO metabolites were due to increased
dietary intake of the diabetic rats [27] (food consumptionlites and cortical renal NOS activity associated with a
decrease in nNOS activity and immunoreactivity in the was not controlled in most of those studies) or increased
organ production of NO metabolites because of highermacula densa. These changes in both urinary metabolites
and nNOS activity were observed during the induction levels of tissue free radicals as the course of DM pro-
gressed. The recent study by Sugimoto et al discussedof early experimental diabetes at a stage when renal
hyperfiltration and kidney growth is most evident [1–3]. previously in this article supports the idea that urinary
NO metabolites increase only after the diabetic state isThe results presented previously in this article suggest
that there is a link between the decrease in urinary NO prolonged [20]. These workers did not see an increase
in NO metabolites until the second week of DM, whichmetabolites and the reduction in nNOS activity in the
macula densa, as we did not find any other changes in paralleled the increase in cortical eNOS activity and was
blocked by the NOS inhibitor L-NAME [20]. It is possi-other NOS isoforms induced by the early diabetic state.
Renal medulla NOS activity is negligible in either the ble that there is a biphasic pattern in renal NO produc-
tion in experimental DM. As was shown recently bynormal or diabetic state. In the cortex, there is minimal
iNOS activity, and the levels of eNOS protein and nNOS Pieper, the disease duration is an important factor in
the NO-mediated endothelium relaxation of large arterymRNA did not change in the cortical homogenates; there
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[28]. In preliminary experiments, the urinary excretion the macula densa [34]. It is possible that reduced local-
ized NO production in the macula densa may enhanceof NO metabolites decreases in the first week after the
induction of diabetes compared with control rats. At two the effect of angiotensin II on the EA, thereby causing
vasoconstriction of the EA that is greater than the angio-weeks, we noted an increase that was very significant at
five weeks. The same phenomena is seen in Wistar rats, tensin II-mediated vasoconstriction of the AA. This, in
turn, would cause elevated intraglomerular pressure andwith the only difference being that the increase in urinary
NO metabolites begins earlier, at two weeks after the increased GFR in the early diabetic state. The later in-
crease in eNOS, which is primarily located in the afferentinduction of diabetes (A. Iaina, unpublished observation).
Experiments are now being conducted in our laboratory arterioles as shown by Sugimoto et al, would result in
vasodilation of the AA, thereby sustaining continuedto determine the mechanism for this biphasic response
in urinary NO metabolites in response to diabetes. It is renal hyperfiltration [20].
In conclusion, we have shown that in early experimen-possible that the early decline in urinary NO metabolites
reflects a decrease in nNOS activity and protein levels tal DM, there is a reduction in macula densa nNOS,
which is associated with hyperfiltration, renal hypertro-in the macula densa followed by increased renal excre-
tion of NO metabolites beginning after the first week phy, and a decrease in urinary NO metabolites. Further
studies are necessary to define the causal relationshipthat results from an increase in eNOS activity.
Our study would suggest that the decline in nNOS between the decrease in nNOS in the macula densa, and
the increased hyperfiltration and hypertrophy seen inactivity is an early change that is temporally related to
renal hyperfiltration and renal growth seen in the first the first week of experimental DM.
week of experimental DM. As was suggested by Craven,
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